34 Grants (Page 1 of 2)
2022
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
Lu, Xiongbin and Zhang, Xinna
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA260274-01A1), $501,827USD, 2022-01-01 -- 2026-12-31
2021
Identification of USP13 as a therapeutic target for ovarian cancer
LU, XIONGBIN and Nagrath, Deepak
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA222251-04), $357,498USD, 2018-02-02 -- 2023-01-31
 
Nanotechnology for targeted therapy and fundamental understanding of therapeutic resistance in triple negative breast cancer
HE, XIAOMING and LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA243023-02), $455,670USD, 2020-04-01 -- 2025-03-31
 
Targeting HER2-low breast cancer with 17p loss
LU, XIONGBIN⋅Schneider, Bryan P and Zhang, Xinna
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 2R01CA203737-07), $535,448USD, 2016-04-01 -- 2026-04-30
2020
Identification of USP13 as a therapeutic target for ovarian cancer
LU, XIONGBIN and Nagrath, Deepak
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA222251-03), $360,271USD, 2018-02-02 -- 2023-01-31
 
Nanotechnology enabled targeting of p53 deficiency in human cancer
HE, XIAOMING and LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA206366-05), $463,867USD, 2018-07-01 -- 2021-06-30
 
Nanotechnology enabled targeting of p53 deficiency in human cancer
HE, XIAOMING and LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA206366-04S1), $42,815USD, 2018-07-01 -- 2021-06-30
 
Nanotechnology for targeted therapy and fundamental understanding of therapeutic resistance in triple negative breast cancer
HE, XIAOMING and LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA243023-01A1), $472,539USD, 2020-04-01 -- 2025-03-31
 
Targeting Human Cancers with Hemizygous Deletion of TP53
LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA203737-06), $360,281USD, 2017-08-09 -- 2021-03-31
2019
Identification of USP13 as a therapeutic target for ovarian cancer
LU, XIONGBIN and Nagrath, Deepak
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA222251-02), $352,044USD, 02/02/2018 -- 01/31/2023
 
Nanotechnology enabled targeting of p53 deficiency in human cancer
HE, XIAOMING and LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA206366-04), $343,342USD, 07/01/2018 -- 06/30/2021
 
Targeting Human Cancers with Hemizygous Deletion of TP53
LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA203737-05), $349,472USD, 08/09/2017 -- 03/31/2021
2018
Engineering Antibody Drug Conjugates To Target P53-Defective Triple Negative Breast Cancer
LU, XIONGBIN and WANG, JIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA213535-02), $207,797USD, 06/13/2017 -- 05/31/2019
 
Identification of USP13 as a therapeutic target for ovarian cancer
LU, XIONGBIN and Nagrath, Deepak
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA222251-01), $379,129USD, 02/02/2018 -- 01/31/2023
 
Nanotechnology enabled targeting of p53 deficiency in human cancer
HE, XIAOMING and LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 7R01CA206366-03), $353,962USD, 07/01/2018 -- 06/30/2021
 
Targeting Human Cancers with Hemizygous Deletion of TP53
LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA203737-04), $324,252USD, 08/09/2017 -- 03/31/2021
2017
Engineering Antibody Drug Conjugates To Target P53-Defective Triple Negative Breast Cancer
LU, XIONGBIN and WANG, JIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA213535-01A1), $185,933USD, 06/13/2017 -- 05/31/2019
 
Nanotechnology enabled targeting of p53 deficiency in human cancer
HE, XIAOMING and LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA206366-02), $359,138USD, 07/08/2016 -- 06/30/2021
 
Targeting Human Cancers with Hemizygous Deletion of TP53
LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 7R01CA203737-03), $360,281USD, 08/09/2017 -- 03/31/2021
2016
Nanotechnology enabled targeting of p53 deficiency in human cancer
HE, XIAOMING and LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA206366-01A1), $371,490USD, 07/08/2016 -- 06/30/2021
 
Targeting Human Cancers with Hemizygous Deletion of TP53
LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA203737-01), $366,000USD, 04/01/2016 -- 03/31/2021
 
Ubiquitin specific peptidases as redox sensor in oncogene-induced p53 signaling
LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA185742-02), $174,000USD, 03/01/2015 -- 02/28/2017
 
Ubiquitin specific peptidases as redox sensor in oncogene-induced p53 signaling
LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 7R21CA185742-03), $165,285USD, 08/09/2017 -- 02/28/2018
2015
Ubiquitin specific peptidases as redox sensor in oncogene-induced p53 signaling
LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA185742-01A1), $208,800USD, 03/01/2015 -- 02/28/2017
2013
Regulation of the ATM/ATR-p53 DNA Damage Signaling Pathway by the Wip1 Phosphatas
LU, XIONGBIN
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA136549-05), $298,935USD, 05/01/2009 -- 02/28/2015